NOT FOR PROMOTIONAL USE Kala · .. Innovation In Ophthalmology Corporate Overview September 2022 NOT FOR PROMOTIONAL USE Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements in this press release about Kala's future expectations, plans and prospects, including but not limited to statements about Kala's expectations with respect to potential advan ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Hannah Deresiewicz – Stern Investor Relations Mark Iwicki – Chief Executive Officer Kim Brazzell – Head-R&D and Chief Medical Mary Reumuth – Chief Financial Officer Conference Call Participants Operator Good day. My name is Shantel, and I will be your conference operator today. At this time, I would like to welcome everyone to the Kala Pharmaceuticals Second Quarter 2022 Financial Result ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or othe ...

NOT FOR PROMOTIONAL USE Innovation In Ophthalmology Corporate Overview August 2022 NOT FOR PROMOTIONAL USE Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements in this press release about Kala's future expectations, plans and prospects, including but not limited to statements about Kala's expectations with respect to potential advantages of KPI- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (781) 996-5252 (Registrant's telephone number, including area code) | Securities registered pursuant to Section 12(b) of the Act | | | | --- | --- | --- | | Title of each class | Tra ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Communications Mark Iwicki - Chairman and Chief Executive Officer Todd Bazemore - President and Chief Operating Officer Kim Brazzell - Head of R&D and Chief Medical Officer Mary Reumuth - Chief Financial Officer Conference Call Participants Christopher Neyor - JPMorgan Francois Brisebois - Oppenheimer & Co. Andreas Argyrides ...

Innovation In Ophthalmology CorporateOverview April 2022 NOT FOR PROMOTIONAL USE Disclaimers andNotices 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about our future expectations, plans and prospects, including but not limited to statements about our expectations with respect to and potential advantages of KPI-012, KPI-287 and our SEGRM program, the future development or commercialization of KPI-012, KPI-287 or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or other ju ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q4 2021 Earnings Conference Call March 29, 2022 8:00 AM ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Communications Mark Iwicki - Chairman and Chief Executive Officer Todd Bazemore - President and Chief Operating Officer Kim Brazzell - Head, R&D and Chief Medical Officer Mary Reumuth - Chief Financial Officer Darius Kharabi - Chief Business Officer Conference Call Participants Andreas Argyrides - Wedbush Chris Neyor - JPM ...

Innovation In Ophthalmology Corporate Overview January 2022 NOT FOR PROMOTIONAL USE Disclaimers and Notices This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about our future expectations, plans and prospects, including but not limited to statements about our expectations with respect to and potential advantages of KPI-012, KPI-287 and our SEGRM program, the future development or commercialization of KPI-012, KPI-287 o ...